# Mobileye Global Inc.: financial statements, quarterly

MBLY · Nasdaq · CIK 1910139 · [Technology](/sectors/technology.md) · fiscal year ends Dec 27

Pages: [Overview](/companies/mbly.md) · [Financials](/companies/mbly/financials.md) · [Filings](/companies/mbly/filings.md) · [Insiders](/companies/mbly/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mbly/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-27) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) | Q3 FY2026 (2026-09-26) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [637 d](/filings/0001104659-26-014300.md) | [239](/filings/0001410578-25-000872.md) | [439](/filings/0001410578-25-001498.md) | [486](/filings/0001104659-25-101834.md) | [490 d](/filings/0001104659-26-014300.md) | [438](/filings/0001104659-26-047712.md) | [506](/filings/0001104659-26-086264.md) | [504](/filings/0001104659-26-120226.md) | [446 d](/filings/0001104659-26-014300.md) | [558](/filings/0001104659-26-047712.md) | [508](/filings/0001104659-26-086264.md) | [492](/filings/0001104659-26-120226.md) |
| Cost of revenue | $m | [293 d](/filings/0001104659-26-014300.md) | [185](/filings/0001410578-25-000872.md) | [230](/filings/0001410578-25-001498.md) | [249](/filings/0001104659-25-101834.md) | [249 d](/filings/0001104659-26-014300.md) | [231](/filings/0001104659-26-047712.md) | [254](/filings/0001104659-26-086264.md) | [261](/filings/0001104659-26-120226.md) | [244 d](/filings/0001104659-26-014300.md) | [283](/filings/0001104659-26-047712.md) | [273](/filings/0001104659-26-086264.md) | [231](/filings/0001104659-26-120226.md) |
| Gross profit | $m | [344 d](/filings/0001104659-26-014300.md) | [54.0](/filings/0001410578-25-000872.md) | [209](/filings/0001410578-25-001498.md) | [237](/filings/0001104659-25-101834.md) | [241 d](/filings/0001104659-26-014300.md) | [207](/filings/0001104659-26-047712.md) | [252](/filings/0001104659-26-086264.md) | [243](/filings/0001104659-26-120226.md) | [202 d](/filings/0001104659-26-014300.md) | [275](/filings/0001104659-26-047712.md) | [235](/filings/0001104659-26-086264.md) | [261](/filings/0001104659-26-120226.md) |
| Research and development | $m | [225 d](/filings/0001104659-26-014300.md) | [243](/filings/0001410578-25-000872.md) | [256](/filings/0001410578-25-001498.md) | [303](/filings/0001104659-25-101834.md) | [281 d](/filings/0001104659-26-014300.md) | [275](/filings/0001104659-26-047712.md) | [282](/filings/0001104659-26-086264.md) | [304](/filings/0001104659-26-120226.md) | [290 d](/filings/0001104659-26-014300.md) | [323](/filings/0001104659-26-047712.md) | [207](/filings/0001104659-26-086264.md) | [284](/filings/0001104659-26-120226.md) |
| Operating income | $m | [73.0 d](/filings/0001104659-26-014300.md) | [(238)](/filings/0001410578-25-000872.md) | [(94.0)](/filings/0001410578-25-001498.md) | [(2,807)](/filings/0001104659-25-101834.md) | [(86.0) d](/filings/0001104659-26-014300.md) | [(117)](/filings/0001104659-26-047712.md) | [(74.0)](/filings/0001104659-26-086264.md) | [(109)](/filings/0001104659-26-120226.md) | [(140) d](/filings/0001104659-26-014300.md) | [(3,896)](/filings/0001104659-26-047712.md) | [(30.0)](/filings/0001104659-26-086264.md) | [(82.0)](/filings/0001104659-26-120226.md) |
| Income tax | $m | [21.0 d](/filings/0001104659-26-014300.md) | [(3.0)](/filings/0001410578-25-000872.md) | [5.0](/filings/0001410578-25-001498.md) | [(78.0)](/filings/0001104659-25-101834.md) | [3.0 d](/filings/0001104659-26-014300.md) | [3.0](/filings/0001104659-26-047712.md) | [6.0](/filings/0001104659-26-086264.md) | [4.0](/filings/0001104659-26-120226.md) | [2.0 d](/filings/0001104659-26-014300.md) | [(64.0)](/filings/0001104659-26-047712.md) | [4.0](/filings/0001104659-26-086264.md) | [(1.0)](/filings/0001104659-26-120226.md) |
| Net income | $m | [63.0 d](/filings/0001104659-26-014300.md) | [(218)](/filings/0001410578-25-000872.md) | [(86.0)](/filings/0001410578-25-001498.md) | [(2,715)](/filings/0001104659-25-101834.md) | [(71.0) d](/filings/0001104659-26-014300.md) | [(102)](/filings/0001104659-26-047712.md) | [(67.0)](/filings/0001104659-26-086264.md) | [(96.0)](/filings/0001104659-26-120226.md) | [(127) d](/filings/0001104659-26-014300.md) | [(3,818)](/filings/0001104659-26-047712.md) | [(21.0)](/filings/0001104659-26-086264.md) | [(67.0)](/filings/0001104659-26-120226.md) |
| Diluted EPS | $ per share | not reported | [(0.27)](/filings/0001410578-25-000872.md) | [(0.11)](/filings/0001410578-25-001498.md) | [(3.35)](/filings/0001104659-25-101834.md) | not reported | [(0.13)](/filings/0001104659-26-047712.md) | [(0.08)](/filings/0001104659-26-086264.md) | [(0.12)](/filings/0001104659-26-120226.md) | not reported | [(4.68)](/filings/0001104659-26-047712.md) | [(0.03)](/filings/0001104659-26-086264.md) | [(0.08)](/filings/0001104659-26-120226.md) |
| Basic EPS | $ per share | not reported | [(0.27)](/filings/0001410578-25-000872.md) | [(0.11)](/filings/0001410578-25-001498.md) | [(3.35)](/filings/0001104659-25-101834.md) | not reported | [(0.13)](/filings/0001104659-26-047712.md) | [(0.08)](/filings/0001104659-26-086264.md) | [(0.12)](/filings/0001104659-26-120226.md) | not reported | [(4.68)](/filings/0001104659-26-047712.md) | [(0.03)](/filings/0001104659-26-086264.md) | [(0.08)](/filings/0001104659-26-120226.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | FY2025 (2025-12-27) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) | Q3 FY2026 (2026-09-26) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [1.2](/filings/0001410578-25-000127.md) | [1.2](/filings/0001410578-24-000632.md) | [1.2](/filings/0001410578-24-001171.md) | [1.3](/filings/0001410578-24-001734.md) | [1.4](/filings/0001104659-26-014300.md) | [1.5](/filings/0001410578-25-000872.md) | [1.7](/filings/0001410578-25-001498.md) | [1.7](/filings/0001104659-25-101834.md) | [1.8](/filings/0001104659-26-120226.md) | [1.2](/filings/0001104659-26-047712.md) | [1.3](/filings/0001104659-26-086264.md) | [1.3](/filings/0001104659-26-120226.md) |
| Current assets | $bn | [2.1](/filings/0001410578-25-000127.md) | [1.9](/filings/0001410578-24-000632.md) | [2.0](/filings/0001410578-24-001171.md) | [2.1](/filings/0001410578-24-001734.md) | [2.2](/filings/0001104659-26-014300.md) | [2.2](/filings/0001410578-25-000872.md) | [2.4](/filings/0001410578-25-001498.md) | [2.4](/filings/0001104659-25-101834.md) | [2.5](/filings/0001104659-26-120226.md) | [2.0](/filings/0001104659-26-047712.md) | [2.1](/filings/0001104659-26-086264.md) | [2.1](/filings/0001104659-26-120226.md) |
| Total assets | $bn | [15.6](/filings/0001410578-25-000127.md) | [15.3](/filings/0001410578-24-000632.md) | [15.3](/filings/0001410578-24-001171.md) | [12.6](/filings/0001410578-24-001734.md) | [12.6](/filings/0001104659-26-014300.md) | [12.5](/filings/0001410578-25-000872.md) | [12.6](/filings/0001410578-25-001498.md) | [12.5](/filings/0001104659-25-101834.md) | [12.5](/filings/0001104659-26-120226.md) | [8.7](/filings/0001104659-26-047712.md) | [8.8](/filings/0001104659-26-086264.md) | [8.9](/filings/0001104659-26-120226.md) |
| Current liabilities | $bn | [0.4](/filings/0001410578-25-000127.md) | [0.3](/filings/0001410578-24-000632.md) | [0.3](/filings/0001410578-24-001171.md) | [0.4](/filings/0001410578-24-001734.md) | [0.3](/filings/0001104659-26-014300.md) | [0.3](/filings/0001410578-25-000872.md) | [0.3](/filings/0001410578-25-001498.md) | [0.4](/filings/0001104659-25-101834.md) | [0.4](/filings/0001104659-26-120226.md) | [0.4](/filings/0001104659-26-047712.md) | [0.5](/filings/0001104659-26-086264.md) | [0.5](/filings/0001104659-26-120226.md) |
| Total liabilities | $bn | [0.7](/filings/0001410578-25-000127.md) | [0.6](/filings/0001410578-24-000632.md) | [0.6](/filings/0001410578-24-001171.md) | [0.5](/filings/0001410578-24-001734.md) | [0.5](/filings/0001104659-26-014300.md) | [0.4](/filings/0001410578-25-000872.md) | [0.5](/filings/0001410578-25-001498.md) | [0.5](/filings/0001104659-25-101834.md) | [0.6](/filings/0001104659-26-120226.md) | [0.6](/filings/0001104659-26-047712.md) | [0.6](/filings/0001104659-26-086264.md) | [0.7](/filings/0001104659-26-120226.md) |
| Shareholders' equity | $bn | [14.9](/filings/0001104659-26-014300.md) | [14.8](/filings/0001410578-25-001498.md) | [14.7](/filings/0001104659-25-101834.md) | [12.1](/filings/0001104659-25-101834.md) | [12.1](/filings/0001104659-26-120226.md) | [12.0](/filings/0001104659-26-086264.md) | [12.1](/filings/0001104659-26-120226.md) | [11.9](/filings/0001104659-26-120226.md) | [11.9](/filings/0001104659-26-120226.md) | [8.2](/filings/0001104659-26-086264.md) | [8.2](/filings/0001104659-26-120226.md) | [8.2](/filings/0001104659-26-120226.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-27) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) | Q3 FY2026 (2026-09-26) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [109 d](/filings/0001104659-26-014300.md) | [40.0](/filings/0001410578-25-000872.md) | [30.0 d](/filings/0001410578-25-001498.md) | [126 d](/filings/0001104659-25-101834.md) | [204 d](/filings/0001104659-26-014300.md) | [109](/filings/0001104659-26-047712.md) | [213 d](/filings/0001104659-26-086264.md) | [167 d](/filings/0001104659-26-120226.md) | [113 d](/filings/0001104659-26-014300.md) | [75.0](/filings/0001104659-26-047712.md) | [135 d](/filings/0001104659-26-086264.md) | [93.0 d](/filings/0001104659-26-120226.md) |
| Capital expenditure | $m | [23.0 d](/filings/0001104659-26-014300.md) | [22.0](/filings/0001410578-25-000872.md) | [24.0 d](/filings/0001410578-25-001498.md) | [22.0 d](/filings/0001104659-25-101834.md) | [13.0 d](/filings/0001104659-26-014300.md) | [14.0](/filings/0001104659-26-047712.md) | [14.0 d](/filings/0001104659-26-086264.md) | [24.0 d](/filings/0001104659-26-120226.md) | [27.0 d](/filings/0001104659-26-014300.md) | [30.0](/filings/0001104659-26-047712.md) | [21.0 d](/filings/0001104659-26-086264.md) | [21.0 d](/filings/0001104659-26-120226.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001104659-26-014300.md) | not reported | [23.5](/filings/0001104659-26-086264.md) | [9.5](/filings/0001104659-26-120226.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-04-01) | Q2 FY2023 (2023-07-01) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) | Q3 FY2026 (2026-09-26) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [802](/filings/0001410578-24-000632.md) | [805](/filings/0001410578-24-001171.md) | [810](/filings/0001410578-24-001734.md) | [806](/filings/0001410578-25-000872.md) | [806](/filings/0001410578-25-001498.md) | [811](/filings/0001104659-25-101834.md) | [812](/filings/0001104659-26-047712.md) | [812](/filings/0001104659-26-086264.md) | [814](/filings/0001104659-26-120226.md) | [817](/filings/0001104659-26-047712.md) | [818](/filings/0001104659-26-086264.md) | [824](/filings/0001104659-26-120226.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 252,403,844 at 2026-10-21, from the cover of the [10-Q filed 2026-10-29](/filings/0001104659-26-120226.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 18:45 ET. No prices; not investment advice.